Wedbush upgrades Achillion Pharmaceuticals (Nasdaq: ACHN) from Neutral to Outperform. Price target $5.

Wedbush analyst says, "Our increased confidence of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE